Literature DB >> 10516706

Thrombotic microangiopathy associated with reactivation of human herpesvirus-6 following high-dose chemotherapy with autologous bone marrow transplantation in young children.

Y Matsuda1, J Hara, H Miyoshi, Y Osugi, H Fujisaki, K Takai, H Ohta, K Tanaka-Taya, K Yamanishi, S Okada.   

Abstract

Thrombotic microangiopathy (TMA) is a serious complication of BMT. Several factors are important in the etiology of TMA, such as cyclosporin A, GVHD, irradiation, intensive conditioning chemotherapy and infection, which cause damage to vascular endothelial cells leading to activation of these cells. We describe two young children with TMA following high-dose chemotherapy with autologous BMT. Development of TMA was accompanied by reactivation of HHV-6, which was identified by both an increase in the copy number of HHV-6 DNA in the peripheral blood and a significant increase in antibody titers to HHV-6. Thus, it was suggested that reactivation of HHV-6 together with high-dose chemotherapy played an important role in the pathogenesis of TMA in these patients. Since HHV-6 is known to infect vascular endothelial cells, and CMV which is virologically closely related to HHV-6, has been reported to be a pathogen that causes TMA, infection with HHV-6 of vascular endothelial cells may induce TMA via damage and activation of these cells.

Entities:  

Mesh:

Year:  1999        PMID: 10516706     DOI: 10.1038/sj.bmt.1702003

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  9 in total

1.  Tacrolimus-related encephalopathy following allogeneic stem cell transplantation in children.

Authors:  Takahisa Kanekiyo; Junichi Hara; Yoshiko Matsuda-Hashii; Hiroyuki Fujisaki; Sadao Tokimasa; Akihisa Sawada; Keiko Kubota; Kuriko Shimono; Katsumi Imai; Keiichi Ozono
Journal:  Int J Hematol       Date:  2005-04       Impact factor: 2.490

2.  Detection of antibodies directed against human herpesvirus 6 U94/REP in sera of patients affected by multiple sclerosis.

Authors:  Elisabetta Caselli; Michela Boni; Arianna Bracci; Antonella Rotola; Claudio Cermelli; Massimiliano Castellazzi; Dario Di Luca; Enzo Cassai
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

Review 3.  Update on human herpesvirus 6 biology, clinical features, and therapy.

Authors:  Leen De Bolle; Lieve Naesens; Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

Review 4.  Chromosomally integrated human herpesvirus 6: questions and answers.

Authors:  Philip E Pellett; Dharam V Ablashi; Peter F Ambros; Henri Agut; Mary T Caserta; Vincent Descamps; Louis Flamand; Agnès Gautheret-Dejean; Caroline B Hall; Rammurti T Kamble; Uwe Kuehl; Dirk Lassner; Irmeli Lautenschlager; Kristin S Loomis; Mario Luppi; Paolo Lusso; Peter G Medveczky; Jose G Montoya; Yasuko Mori; Masao Ogata; Joshua C Pritchett; Sylvie Rogez; Edward Seto; Katherine N Ward; Tetsushi Yoshikawa; Raymund R Razonable
Journal:  Rev Med Virol       Date:  2011-11-04       Impact factor: 6.989

Review 5.  Human herpesvirus 6 and human herpesvirus 7: emerging pathogens in transplant patients.

Authors:  Duncan A Clark
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.319

6.  Thrombotic microangiopathy in haematopoietic cell transplantation: an update.

Authors:  Evi Stavrou; Hillard M Lazarus
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-11-03       Impact factor: 2.576

7.  Thrombotic Microangiopathy: Multi-Institutional Review of Pediatric Patients Who Underwent HSCT.

Authors:  Archana Ramgopal; Shiva Sridar; Jignesh Dalal; Ramasubramanian Kalpatthi
Journal:  J Pers Med       Date:  2021-05-25

Review 8.  Atypical hemolytic uremic syndrome.

Authors:  David Kavanagh; Tim H Goodship; Anna Richards
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299

9.  Human herpes virus 6 or Epstein-Barr virus were not detected in Guthrie cards from children who later developed leukaemia.

Authors:  G Bogdanovic; A G Jernberg; P Priftakis; L Grillner; B Gustafsson
Journal:  Br J Cancer       Date:  2004-08-31       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.